Clinical Trial Update: Safety of and Immune Response to a Human Parainfluenza Virus Vaccine (rHPIV3cp45) in Healthy Infants [Phase 1]

View source ↗

Summary

Phase 1 study assessing safety and immune response of the recombinant human parainfluenza virus type 3 vaccine rHPIV3cp45 in healthy infants.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Human Parainfluenza Virus Infection

Drugs mentioned

• rHPIV3cp45

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Paramyxoviridae Infections, Virus Diseases | Phase 1 | Status: COMPLETED